Control-relevant erythropoiesis modeling in end-stage renal disease.
Anemia is prevalent in end-stage renal disease (ESRD). The discovery of recombinant human erythropoietin (rHuEPO) over 30 years ago has shifted the treatment of anemia for patients on dialysis from blood transfusions to rHuEPO therapy. Many anemia management protocols (AMPs) used by clinicians comprise a set of experience-based rules for weekly-to-monthly titration of rHuEPO doses based on hemoglobin (Hb) measurements. In order to facilitate the design of an AMP using model-based feedback control theory, we present a physiologically relevant erythropoiesis model and demonstrate its applicability using clinical data.
Yossi
Y
Chait
Joseph
J
Horowitz
Brendan
B
Nichols
Rajiv P
RP
Shrestha
C V
CV
Hollot
Michael J
MJ
Germain
D000465:Algorithms; D000740:Anemia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016903:Drug Monitoring; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008954:Models, Biological; D015233:Models, Statistical; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin